tirzepatide and multiple sclerosis Glucagon-like peptide-1 medicines in neurological psychiatric disorders: Cell Reports Medicine The Role of Glucagon-Like Peptide-1

In April 2005 the US Food and Drugs Administration (FDA) approved a synthetic version, called exenatide, to treat type 2 diabetic patients unable to sufficiently control their blood sugar levels with other diabetic medications like metformin, and sulfonylureas

However, concerns exist: some patients plateau, some resume weight gain when stopping therapy, and long-term side effects (GI issues, pancreatitis, gallstones) are under scrutiny

Medications that target insulin resistance can also aid in weight loss, providing dual benefits for patients struggling with both conditions

However, the reno-protective effects of SGLT2 inhibitor in DKD with microalbuminuria has not yet been fully proven